Bradley Uyemura, Natalie S Callander
Maintenance therapy has been one of the cornerstones of multiple myeloma (MM) management, aiming to prolong remission duration, delay progression, and improve survival while preserving quality of life. Following advances in induction regimens and the widespread use of autologous stem cell transplantation, the role of post-transplant maintenance therapy has evolved from interferon-based approaches to continuous therapy with immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, and more recently, bispecific antibodies. This review summarizes the modern data of maintenance therapies for MM while also discussing emerging approaches with minimal residual disease-based strategies and additional novel agents.